Fully Deleted Adenovirus Persistently Expressing GAA Accomplishes Long-Term Skeletal Muscle Glycogen Correction in Tolerant and Nontolerant GSD-II Mice

This publication has 33 references indexed in Scilit:

• Primary adenovirus-specific cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation
  Gene Therapy, 2005
• Multiple muscles in the AMD quail can be ?cross-corrected? of pathologic glycogen accumulation after intravenous injection of an [E1-, polymerase-] adenovirus vector encoding human acid-?-glucosidase
  The Journal of Gene Medicine, 2002
• Efficacy of Gene Therapy for a Prototypical Lysosomal Storage Disease (GSD-II) Is Critically Dependent on Vector Dose, Transgene Promoter, and the Tissues Targeted for Vector Transduction
  Molecular Therapy, 2002
• Long-Term Efficacy after [E1^-, polymerase^-] Adenovirus-Mediated Transfer of Human Acid-α-Glucosidase Gene into Glycogen Storage Disease Type II Knockout Mice
  Human Gene Therapy, 2001
• Towards a molecular therapy for glycogen storage disease type II (Pompe disease)
  Molecular Medicine Today, 2000
• Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling
  European Journal of Human Genetics, 1999
• Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase
  Proceedings of the National Academy of Sciences, 1999
• A diagnostic protocol for adult-onset glycogen storage disease type II
  Neurology, 1999
• Persistence of an [E1-, Polymerase-] Adenovirus Vector Despite Transduction of a Neoantigen into Immune-Competent Mice
  Human Gene Therapy, 1999
• Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease
  American Journal of Medical Genetics, 1998